Megakaryocytic hyperplasia refers to an abnormal increase in the number of megakaryocytes, the large bone marrow cells responsible for producing platelets. It shows up on bone marrow biopsies across a surprisingly wide range of conditions, from iron deficiency to blood cancers. What makes it diagnostically valuable is not just the increase itself but the specific shapes, sizes, and clustering patterns of the expanded megakaryocytes, which differ meaningfully depending on the underlying cause.
What Megakaryocytes Do and What Drives Their Growth
Megakaryocytes are unusual cells. They are among the largest in the bone marrow, and their main job is assembling platelets by extending long arm-like projections called proplatelets into the bloodstream, where they fragment into thousands of individual platelets. The primary signal that tells the body to make more megakaryocytes is thrombopoietin, or TPO, a growth factor produced mainly by the liver.1PubMed Central. Thrombopoietin and hematopoietic stem cells TPO binds to a receptor called c-Mpl on the surface of megakaryocyte precursors, triggering a signaling cascade that drives both proliferation and maturation of these cells.2PubMed. Megakaryocyte development and platelet production
When the body needs more platelets, whether because of bleeding, infection, or other stress, TPO levels rise and megakaryocyte numbers increase. That part is normal physiology. Megakaryocytic hyperplasia becomes clinically significant when the increase is persistent, disproportionate, or accompanied by abnormal-looking cells, because those features suggest something beyond a temporary physiological response.
Reactive Causes That Can Mimic Serious Disease
Not every case of megakaryocytic hyperplasia points to a blood cancer. Several benign or treatable conditions can expand the megakaryocyte pool in the bone marrow, and recognizing these is essential to avoid unnecessary alarm or invasive follow-up.
Iron Deficiency
Iron deficiency is one of the most common nutritional disorders worldwide, and it turns out to directly influence megakaryocyte production. When iron levels in the bone marrow drop, progenitor cells that normally decide between becoming red blood cells or megakaryocytes get steered toward the megakaryocyte path. Research in both mouse models and human cord blood cultures has demonstrated that low iron biases these progenitor cells toward megakaryocyte commitment and enhances proplatelet formation.3PubMed Central. Low iron promotes megakaryocytic commitment of megakaryocytic-erythroid progenitors in humans and mice Cell culture experiments confirm the same picture: iron deficiency increases the percentage of cells expressing megakaryocyte markers and boosts the formation of proplatelet structures.4PubMed Central. Increased expression of HIF2α during iron deficiency-associated megakaryocytic differentiation – Section: RESULTS AND CONCLUSIONS This helps explain why people with severe iron deficiency sometimes have elevated platelet counts, a finding that can be confusing on a blood test if the iron deficiency itself goes unrecognized.
Drug-Induced Expansion
Certain medications can trigger megakaryocytic hyperplasia as an expected pharmacological effect. TPO receptor agonists, drugs used to treat immune thrombocytopenia by stimulating platelet production, cause the bone marrow to become hypercellular. On biopsy, the megakaryocytes increase in number and acquire features like pleomorphism (variation in size and shape), nuclear hyperlobulation, and a tendency to form clusters.5PubMed. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities A slight increase in reticulin fibrosis has also been observed during therapy, though collagen fibrosis was never seen in the studied cases. These biopsy changes can look worryingly similar to myeloproliferative neoplasms, making clinical context indispensable.
Growth factors given after chemotherapy can also provoke transient megakaryocyte expansion. One reported case involved a patient treated with granulocyte-macrophage colony-stimulating factor after chemotherapy for acute myeloid leukemia, whose follow-up biopsy showed markedly increased megakaryocytes, reticulin fibrosis, and a high platelet count. These changes resolved on subsequent biopsies, consistent with a temporary reactive process rather than a new disease.6American Journal of Clinical Pathology. Myeloproliferative Neoplasm or Reactive Process? A Rare Case of Acute Myeloid Leukemia and Transient Post-Treatment Megakaryocytic Hyperplasia with JAK-2 Mutation
Paraneoplastic Thrombocytosis
Some solid tumors, particularly ovarian cancer, stimulate megakaryocyte expansion indirectly. The mechanism involves tumor-derived interleukin-6, which travels to the liver and ramps up the production of TPO. The result is elevated platelet counts driven by increased megakaryopoiesis in the bone marrow.7PubMed Central. Paraneoplastic thrombocytosis in ovarian cancer – Section: RESULTS In mouse models of ovarian cancer, blocking this interleukin-6/TPO loop reduced both the thrombocytosis and tumor growth. For clinicians, recognizing that an elevated platelet count and megakaryocytic hyperplasia can be a paraneoplastic phenomenon matters because the treatment target is the underlying tumor, not the blood counts themselves.
Myeloproliferative Neoplasms and the Central Role of Megakaryocytes
The conditions most strongly associated with megakaryocytic hyperplasia are the myeloproliferative neoplasms, a family of blood cancers in which the bone marrow overproduces one or more cell types. In these diseases, megakaryocytes are not just bystanders; they are among the main drivers of disease progression, contributing to the fibrosis and inflammation that reshape the bone marrow over time.8PubMed Central. The Role of Megakaryocytes in Myelofibrosis
Essential thrombocythemia is one of the myeloproliferative neoplasms most directly defined by megakaryocyte abnormalities. It is associated with mutations in JAK2, CALR, or MPL genes, and the World Health Organization diagnostic criteria explicitly include both molecular findings and the appearance of megakaryocytes on bone marrow biopsy.9PubMed Central. Different Shapes Of Megakaryocytes In Essential Thrombocythemia In fact, the diagnostic criteria for essential thrombocythemia formally require megakaryocytic hyperplasia, defined as increased megakaryocyte number and size, without collagen fibrosis.10Leukemia & Lymphoma. Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis
Polycythemia vera shows a different but equally characteristic pattern. Here, the bone marrow is hypercellular with proliferation across all three lineages, meaning red cells, white cells, and megakaryocytes are all expanding. The megakaryocytes form loose clusters and show a striking range in size, from small to giant forms, with deeply lobulated nuclei. This pleomorphous appearance, without obvious dysplastic changes, is considered a hallmark finding that helps distinguish early polycythemia vera from secondary causes of elevated red blood cell counts.11Haematologica. The value of bone marrow histology in differentiating between early stage Polycythemia vera and secondary (reactive) Polycythemias12PubMed. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia)
In primary myelofibrosis, the megakaryocytes take on an even more central and destructive role. Single-cell RNA sequencing of bone marrow from patients with overt myelofibrosis has revealed that hematopoietic stem and progenitor cells become skewed toward the megakaryocyte lineage, and a specific megakaryocyte subset enriched for markers associated with fibrosis is dramatically expanded.13PubMed Central. Different inflammatory, fibrotic, and immunological signatures between pre-fibrotic and overt primary myelofibrosis In other words, the megakaryocytes themselves are among the cells actively depositing the scar tissue that progressively replaces normal bone marrow.
Chronic myeloid leukemia rounds out the myeloproliferative spectrum with yet another distinctive megakaryocyte pattern. Rather than the giant pleomorphic forms of polycythemia vera, chronic myeloid leukemia is characterized by unusually small megakaryocytes, sometimes called dwarf-like or micromegakaryocytes, which predominate especially in the roughly 30% of cases classified as “megakaryocyte-rich” subtypes.14PubMed. Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders – aids to diagnosis and classification
Why Megakaryocyte Shape Matters More Than Megakaryocyte Number
If you step back and look at these conditions side by side, a pattern emerges: nearly all of them show increased megakaryocytes, but the increase alone does not point to a specific diagnosis. What separates one condition from another is how the megakaryocytes look, how big or small they are, what their nuclei look like, and how they arrange themselves in the marrow.
This is where pathology becomes something close to visual pattern recognition. A pathologist examining a bone marrow biopsy looks for several distinguishing morphological signatures:
- Pleomorphic clusters: Small to giant megakaryocytes with deeply lobulated nuclei lying next to each other, typically seen in polycythemia vera and idiopathic myelofibrosis.
- Large mature forms: Increased but relatively normal-looking megakaryocytes with hyperlobulated nuclei, characteristic of essential thrombocythemia, especially MPL-mutated cases.
- Micromegakaryocytes: Abnormally small forms that dominate in chronic myeloid leukemia.
- Hypolobated mononuclear forms: Megakaryocytes with simplified, single-lobed nuclei, a signature finding in myelodysplastic syndrome with deletion of chromosome 5q.15PubMed Central. Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion
The use of antibodies directed against platelet surface markers, such as CD61, has improved the ability to visualize and characterize megakaryocytes in routine bone marrow biopsies. This immunohistochemical staining provides a rapid and reproducible way to assess megakaryocyte size, shape, and distribution, which can help resolve ambiguous cases.16PubMed. Megakaryocytes in myelodysplasia: an immunohistochemical study on bone marrow trephines
How Specific Mutations Shape Megakaryocyte Appearance
Molecular testing has added a new layer to the diagnostic process, and it turns out that different driver mutations produce detectably different megakaryocyte morphologies. This is clinically useful because it means a pathologist looking at a biopsy can sometimes predict the mutation before the molecular results come back.
In cases driven by CALR mutations, the bone marrow tends to show clusters of large, immature-looking megakaryocytes with bulky, hyperchromatic nuclei. These have a distinctive bulbous quality that is not seen in other mutation types. JAK2-mutated essential thrombocythemia and polycythemia vera, by contrast, show the pleomorphous pattern described earlier. And MPL-mutated cases stand out with giant megakaryocytes that have dramatically hyperlobulated nuclei, sometimes described as “stag-horn-like.”17PubMed Central. 2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications
These mutation-specific patterns matter for staging and prognosis. CALR-mutated disease tends to carry a somewhat different risk profile than JAK2-mutated disease, and knowing the mutation type helps guide decisions about monitoring and treatment intensity. The interplay between what the pathologist sees under the microscope and what the molecular lab reports creates a more complete picture than either discipline alone.
When Reactive and Neoplastic Causes Overlap
One of the trickiest diagnostic scenarios arises when a patient with a known non-cancerous condition develops biopsy features that look like a myeloproliferative neoplasm. The case described earlier of post-chemotherapy megakaryocytic hyperplasia illustrates this well. That patient’s biopsy showed markedly increased megakaryocytes, reticulin fibrosis, and a platelet count above 700,000 per microliter, all of which could suggest a myeloproliferative neoplasm. Molecular testing then revealed a JAK2 V617F mutation, which made the picture even more ambiguous. However, when a follow-up biopsy showed resolving hyperplasia, normalizing platelet counts, and complete resolution of fibrosis, the transient nature of the changes favored a reactive process, even though the JAK2 mutation persisted and suggested an underlying, previously undetected clonal disorder.6American Journal of Clinical Pathology. Myeloproliferative Neoplasm or Reactive Process? A Rare Case of Acute Myeloid Leukemia and Transient Post-Treatment Megakaryocytic Hyperplasia with JAK-2 Mutation
Cases like this underscore a principle that runs through the entire diagnostic process: no single finding, whether it is the megakaryocyte count, the morphology, the molecular mutation, or the platelet count, is sufficient on its own. Diagnosis requires integrating all of them with the clinical timeline. A biopsy snapshot captures one moment, but whether the findings are stable, worsening, or resolving often tells you more than the snapshot itself.
Thrombotic and Bleeding Complications
Beyond their diagnostic role, abnormal megakaryocytes have direct clinical consequences. Roughly 30 to 40 percent of patients with polycythemia vera or essential thrombocythemia experience thrombotic events, including strokes, deep vein thrombosis, and clots in unusual sites like the splanchnic veins. Microcirculatory disturbances, which cause symptoms like burning pain in the fingers and toes, headaches, and visual changes, are also common. At the other end of the spectrum, spontaneous bleeding, particularly from the gastrointestinal tract, becomes more prevalent in myelofibrosis and advanced stages of chronic myeloid leukemia.18Hämostaseologie. Megakaryocytes and Platelets as the Main Cause for Vascular Events in Chronic Myeloproliferative Disorders
These complications are not just a consequence of having too many platelets. The platelets produced by abnormal megakaryocytes are themselves functionally aberrant. They may be hyperactivated and prone to clumping, or paradoxically dysfunctional and unable to form stable clots. This dual risk of both clotting and bleeding in the same patient population is one of the genuinely tricky aspects of managing myeloproliferative neoplasms and speaks to why megakaryocyte biology matters well beyond the pathology report.
Hereditary Thrombocytosis and Germline Variants
Most discussions of megakaryocytic hyperplasia focus on acquired conditions, but there is also a hereditary form worth knowing about. Hereditary thrombocytosis is a rare condition in which germline mutations in the same genes involved in acquired myeloproliferative neoplasms, specifically THPO (the gene encoding thrombopoietin), MPL, and JAK2, cause lifelong overactivation of the TPO signaling pathway. The result is megakaryocyte hyperplasia from birth, with persistently elevated platelet counts that can be mistaken for essential thrombocythemia.19Nature. Germline JAK2 R564Q variants presenting as hereditary thrombocytosis: case report
The distinction between hereditary thrombocytosis and essential thrombocythemia is not academic. Essential thrombocythemia is a clonal neoplasm that carries risks of disease transformation and requires ongoing monitoring and sometimes cytoreductive therapy. Hereditary thrombocytosis, while it can cause thrombotic events, generally has a more stable course and does not transform into leukemia. Misdiagnosis can lead to years of inappropriate treatment. Family history and genetic testing of germline DNA, rather than just the bone marrow, are the keys to telling them apart. In a young patient with unexplained thrombocytosis and megakaryocytic hyperplasia, especially if relatives share the same blood count abnormality, hereditary thrombocytosis should be on the differential.
Myelodysplastic Syndromes and Paradoxical Megakaryocyte Findings
Myelodysplastic syndromes are bone marrow disorders characterized by ineffective blood cell production and a risk of transforming into acute leukemia. In most types, the bone marrow is hypercellular but the blood counts are low because the cells being produced are defective. Megakaryocytes in myelodysplastic syndromes are typically dysplastic, meaning they look abnormal under the microscope, but whether their numbers are increased, decreased, or normal depends on the specific subtype.
The myelodysplastic syndrome associated with deletion of chromosome 5q stands out because it frequently features normal to increased megakaryocyte numbers, meaning it can present with genuine megakaryocytic hyperplasia. The megakaryocytes themselves have a distinctive and recognizable morphology: small, with hypolobated or entirely mononuclear nuclei, a stark contrast to the hyperlobulated giants of polycythemia vera or the bulky forms of CALR-mutated thrombocythemia.15PubMed Central. Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion This subtype also has a clinically favorable profile, with lower risk of leukemic transformation and a characteristically good response to lenalidomide. Recognizing the morphological pattern can therefore have immediate treatment implications.